Brainstorm Cell Therapeutics Inc (NAS:BCLI)
$ 0.484 -0.0161 (-3.22%) Market Cap: 33.08 Mil Enterprise Value: 34.15 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 38/100

Q4 2022 Brainstorm Cell Therapeutics Inc Earnings Call Transcript

Mar 30, 2023 / 12:00PM GMT
Release Date Price: $2.5 (+2.46%)
Operator

Greetings, and welcome to the BrainStorm Cell Therapeutics' fourth-quarter 2022 earnings call. (Operator Instructions) As a reminder, this call is being recorded. And I would now like to introduce your host for today's call, Michael Wood of LifeSci Advisors. Mr. Wood, you may begin.

Michael Wood
LifeSci Advisors, LLC - IR

Good morning, and thank you for joining us. Earlier today, BrainStorm issued a press release with its financial results for the full year 2022, including a corporate update. Before passing off to the company management for prepared remarks, I'd like to remind listeners that this conference call and webcast will contain numerous statements, descriptions, forecasts, and projections regarding BrainStorm Cell Therapeutics and its potential future business operations, and performance, statements regarding the market potential of the treatment of neurodegeneration such as ALS, the sufficiency of the company's existing capital resources for continuing operations into 2023 and beyond, the safety and clinical effectiveness of the NurOwn technology

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot